OTCMKTS:ATBPF

Antibe Therapeutics News Headlines

$0.98
+0.02 (+2.09 %)
(As of 09/22/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.96
$0.98
50-Day Range
$0.81
$2.89
52-Week Range
$0.69
$5.88
Volume53,249 shs
Average Volume42,145 shs
Market Capitalization$50.45 million
P/E RatioN/A
Dividend YieldN/A
Beta0.41

Media Mentions By Week

Antibe Therapeutics Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

ATBPF
News Sentiment

0.00

0.37

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

ATBPF Articles
This Week

0

0

ATBPF Articles
Average Week

Get Antibe Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATBPF and its competitors with MarketBeat's FREE daily newsletter.

Antibe Therapeutics (OTCMKTS ATBPF) News Headlines Today

SourceHeadline
Antibe Therapeutics Inc. (OTCMKTS:ATBPF) Short Interest UpdateAntibe Therapeutics Inc. (OTCMKTS:ATBPF) Short Interest Update
americanbankingnews.com - September 14 at 3:16 PM
Antibe Therapeutics Announces Results of 2021 Annual MeetingAntibe Therapeutics Announces Results of 2021 Annual Meeting
finance.yahoo.com - August 19 at 6:04 PM
Antibe Therapeutics Reports Q1 2022 Interim Financial and Operating ResultsAntibe Therapeutics Reports Q1 2022 Interim Financial and Operating Results
businesswire.com - August 17 at 7:56 AM
ATE.TO: Unexpected Liver Enzyme Elevations Leads to Pause in AME Trial…ATE.TO: Unexpected Liver Enzyme Elevations Leads to Pause in AME Trial…
finance.yahoo.com - August 4 at 6:03 PM
ATE.TO: Phase 3 Enabling Activities Ongoing; Phase 3 Adaptive Trial to Initiate 1Q22…ATE.TO: Phase 3 Enabling Activities Ongoing; Phase 3 Adaptive Trial to Initiate 1Q22…
finance.yahoo.com - July 1 at 12:31 PM
Antibe Therapeutics Collaborates With Dalriada Drug Discovery to Accelerate Pipeline ExpansionAntibe Therapeutics Collaborates With Dalriada Drug Discovery to Accelerate Pipeline Expansion
finance.yahoo.com - June 25 at 8:49 AM
Antibe Therapeutics Announces Agreement to Unify Intellectual Property OwnershipAntibe Therapeutics Announces Agreement to Unify Intellectual Property Ownership
finance.yahoo.com - May 7 at 8:51 AM
Antibe Therapeutics to Present at 2021 Bloom Burton & Co. Healthcare Investor ConferenceAntibe Therapeutics to Present at 2021 Bloom Burton & Co. Healthcare Investor Conference
finance.yahoo.com - April 14 at 8:55 AM
Antibe Therapeutics to Present at Upcoming Virtual Investor ConferencesAntibe Therapeutics to Present at Upcoming Virtual Investor Conferences
finance.yahoo.com - March 3 at 9:45 AM
Antibe Therapeutics Announces C$35 Million Bought Deal Public OfferingAntibe Therapeutics Announces C$35 Million Bought Deal Public Offering
benzinga.com - February 17 at 6:03 PM
IIROC Trading Halt - ATEIIROC Trading Halt - ATE
finance.yahoo.com - February 17 at 6:03 PM
When Will Antibe Therapeutics Inc. (TSE:ATE) Become Profitable?When Will Antibe Therapeutics Inc. (TSE:ATE) Become Profitable?
finance.yahoo.com - January 22 at 7:23 AM
Antibe Therapeutics adds biotech executive Don Haut to its Partnering Advisory TeamAntibe Therapeutics adds biotech executive Don Haut to its Partnering Advisory Team
proactiveinvestors.com - January 7 at 11:23 AM
ATE.TO: Preparing for Potential Uplisting to NasdaqATE.TO: Preparing for Potential Uplisting to Nasdaq
finance.yahoo.com - December 7 at 4:37 PM
Antibe Therapeutics Reports Q2 2021 Interim Financial and Operating ResultsAntibe Therapeutics Reports Q2 2021 Interim Financial and Operating Results
finance.yahoo.com - November 13 at 10:02 AM
Antibe Therapeutics Receives Conditional Approval to Graduate to the Toronto Stock ExchangeAntibe Therapeutics Receives Conditional Approval to Graduate to the Toronto Stock Exchange
finance.yahoo.com - October 30 at 7:24 AM
If You Had Bought Antibe Therapeutics (CVE:ATE) Shares Three Years Ago You'd Have Earned 289% ReturnsIf You Had Bought Antibe Therapeutics (CVE:ATE) Shares Three Years Ago You'd Have Earned 289% Returns
finance.yahoo.com - October 24 at 1:20 PM
Antibe’s breakthrough osteoarthritis pain relief drug in the spotlight on World Arthritis DayAntibe’s breakthrough osteoarthritis pain relief drug in the spotlight on World Arthritis Day
proactiveinvestors.com - October 12 at 8:38 AM
Antibe Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech SummitAntibe Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
finance.yahoo.com - September 15 at 9:14 AM
ATBPF: Phase 3 Program for Otenaproxesul to Initiate in 2021……ATBPF: Phase 3 Program for Otenaproxesul to Initiate in 2021……
finance.yahoo.com - August 28 at 3:46 PM
ATE.V: Commercial Studies Show Blockbuster Potential for ATB-346…ATE.V: Commercial Studies Show Blockbuster Potential for ATB-346…
finance.yahoo.com - August 6 at 12:49 PM
Antibe Therapeutics to Attend 2018 BIO International Convention to Support Partnering EffortsAntibe Therapeutics to Attend 2018 BIO International Convention to Support Partnering Efforts
www.bloomberg.com - July 20 at 10:58 PM
Get Antibe Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATBPF and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 9/23/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.